IF YOU ARE NEWLY DIAGNOSED, CLICK HERE!
DONATE NOW

Information, Community and Research Funding

The mission of The EHE Foundation is to seek treatments and a cure for Epithelioid Hemangioendothelioma (EHE) by increasing awareness, pursuing scientific research, advocating for and supporting EHE patients, and bridging information between researchers, providers and patients.

HOW TO FIGHT EHE

CONNECT

Signup for our email newsletter below to hear about the latest research, fundraisers and events. Follow us on Facebook. Don’t forget to hit that Like button!

DONATE

Donate and encourage others to donate as well. Attend and support one of the fundraising events held each year. To view the funding needed see our Current Research Page

SHARE

Share the EHE Foundation with the world. Let them know that we are here and that we need funding to fight EHE. Tell them your story and encourage them to help.

IMPORTANT EHE NEWS & TRIALS

The Pledge, Edition 11

We warmly welcome all our readers to this eleventh edition of “The Pledge”, the quarterly newsletter of the EHE Group. We hope you enjoy this newsletter, covering the fourth quarter of 2017.

 

The Pledge PDF Download

Trametinib Trial

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery.

ClinicalTrials.gov Identifier:  NCT03148275

For the last several years Dr.Brian Rubin has been working on unlocking genetic driving mechanism behind EHE progression. His work resulted in identification of a pathway directly involved in supporting of EHE genetic malfunction. During the Lab experiments, Dr Rubin was able to disrupt this pathway with MEK inhibitor.

The clinical trial uses MEK inhibitor Mekinist. The purpose of the study to verify that what Dr.Rubin observed in his Lab actually translates in clinical effect in EHE patients. It is a multi institutional study which makes it very easy for enrollment in different parts of the country. You can see more information using following link.

https://clinicaltrials.gov/ct2/show/NCT03148275

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

ClinicalTrials.gov Identifier: NCT03331250

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE).

-The drug involved in this study is Eribulin

In this research study, the investigators are studying how safe and effective eribulin is in participants with Angiosarcoma or EHE.

Eribulin was created to mimic the structure of a chemical that is released from a sea sponge. The investigators believe that this drug has anti-cancer effects on tumors by blocking proteins called microtubules, among other functions. It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die similar to other drugs that target microtubules

https://clinicaltrials.gov/ct2/show/NCT03331250